Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study

Johnson & Johnson (NYSE:JNJ) is among the most profitable mega cap stocks to buy. On February 6, Johnson & Johnson (NYSE:JNJ) disclosed 12-month pilot-phase data from the OMNY-AF study, which examined the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). Announced during the 31st Annual AF Symposium in Boston, the results reveal that investigators achieved 100% acute procedural success with zero adverse events linked to the procedure. As stated by D ...